Development and validation of a gonadotropin dose selection model for optimized ovarian stimulation in IVF/ICSI: an individual participant data meta-analysis
Human Reproduction Update · 01.03.2025 · 31 (2) · 116-132
DOI: 10.1093/humupd/dmae032 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Human Reproduction Update, online erschienen am 20.12.2024. Verfasst von Nienke Schouten und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division Woman and Baby, Reproductive Medicine, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Ovulation Induction, Fertilization in Vitro, Gonadotropins, Sperm Injections, Intracytoplasmic. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Netherlands Organization for Health Research and Development, The Netherlands Organization for Health Research and Development, Merck B.V..
Abstract (Originalsprache)
BACKGROUND The ovarian response to gonadotropin stimulation varies widely among women, and could impact the probability of live birth as well as treatment risks. Many studies have evaluated the impact of different gonadotropin starting doses, mainly based on predictive variables like ovarian reserve tests (ORT) including anti-Müllerian hormone (AMH), antral follicle count (AFC), and basal follicle-stimulating hormone (bFSH). A Cochrane systematic review revealed that individualizing the gonadotropin starting dose does not affect efficacy in terms of ongoing pregnancy/live birth rates, but may reduce treatment risks such as the development of ovarian hyperstimulation syndrome (OHSS). An individual patient data meta-analysis (IPD-MA) offers a unique opportunity to develop and validate a universal prediction model to help choose the optimal gonadotropin starting dose to minimize treatment risks without affecting efficacy. OBJECTIVE AND RATIONALE The objective of this IPD-MA is to develop and validate a gonadotropin dose-selection model to guide the choice of a gonadotropin starting dose in IVF/ICSI, with the purpose of minimizing treatment risks without compromising live birth rates. SEARCH METHODS Electronic databases including MEDLINE, EMBASE, and CRSO were searched to identify eligible studies. The last search was performed on 13 July 2022. Randomized controlled trials (RCTs) were included if they compared different doses of gonadotropins in women undergoing IVF/ICSI, presented at least one type of ORT, and reported on live birth or ongoing pregnancy. Authors of eligible studies were contacted to share their individual participant data (IPD). IPD and information within publications were used to determine the risk of bias. Generalized linear mixed multilevel models were applied for predictor selection and model development. OUTCOMES A total of 14 RCTs with data of 3455 participants were included. After extensive modeling, women aged 39 years and over were excluded, which resulted in the definitive inclusion of 2907 women. The optimal prediction model for live birth included six predictors: age, gonadotropin starting dose, body mass index, AFC, IVF/ICSI, and AMH. This model had an area under the curve (AUC) of 0.557 (95% confidence interval (CI) from 0.536 to 0.577). The clinically feasible live birth model included age, starting dose, and AMH and had an AUC of 0.554 (95% CI from 0.530 to 0.578). Two models were selected as the optimal model for combined treatment risk, as their performance was equal. One included age, starting dose, AMH, and bFSH; the other also included gonadotropin-releasing hormone (GnRH) analog. The AUCs for both models were 0.769 (95% CI from 0.729 to 0.809). The clinically feasible model for combined treatment risk included age, starting dose, AMH, and GnRH analog, and had an AUC of 0.748 (95% CI from 0.709 to 0.787). WIDER IMPLICATIONS The aim of this study was to create a model including patient characteristics whereby gonadotropin starting dose was predictive of both live birth and treatment risks. The model performed poorly on predicting live birth by modifying the FSH starting dose. On the contrary, predicting treatment risks in terms of OHSS occurrence and management by modifying the gonadotropin starting dose was adequate. This dose-selection model, consisting of easily obtainable patient characteristics, aids in the choice of the optimal gonadotropin starting dose for each individual patient to lower treatment risks and potentially reduce treatment costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division Woman and Baby, Reproductive Medicine, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands.
- Department of Obstetrics and Gynaecology, Monash Medical Centre, Monash University, Clayton, VIC, Australia.
- Acibadem University Faculty of Medicine, Department of Obstetrics and Gynecology, Istanbul University School of Medicine, Istanbul, Turkey.
- Department of Obstetrics and Gynaecology, Institute of Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg University, Gothenburg, Sweden.
- Global Medical Affairs, Research and Development, Merck Healthcare KGaA, Darmstadt, Germany.
- Department of Obstetrics and Gynecology, North Zealand Hospital, Hilleroed, Denmark.
ORCID-Profile: Nienke Schouten, Rui Wang, Ercan Bastu, Christina Bergh, Thomas D'Hooghe, Jesper Friis Petersen, Yacoub Khalaf, Antonio La Marca, Lan Vuong, Louise Lapensée, Sarah Lensen, Åsa Magnusson, Adolfo Allegra, Simone Oudshoorn, Ben Willem Mol, Marinus Eijkemans, Frank Broekmans
Förderung
- Netherlands Organization for Health Research and Development
- The Netherlands Organization for Health Research and Development
- Merck B.V.
- NHMRC
- National Health and Medical Research Council
Zitieren
APA
Schouten, N., Wang, R., Torrance, H., Van Tilborg, T., Bastu, E., Bergh, C., D'Hooghe, T., Friis Petersen, J., Jayaprakasan, K., Khalaf, Y., Klinkert, E., La Marca, A., Vuong, L., Lapensée, L., Lensen, S., Magnusson, Å., Allegra, A., Nyboe Andersen, A., Oudshoorn, S., …, & Broekmans, F. (2025). Development and validation of a gonadotropin dose selection model for optimized ovarian stimulation in IVF/ICSI: an individual participant data meta-analysis. Human Reproduction Update, 31(2), 116-132. https://doi.org/10.1093/humupd/dmae032
Vancouver
Schouten N, Wang R, Torrance H, Van Tilborg T, Bastu E, Bergh C, et al. Development and validation of a gonadotropin dose selection model for optimized ovarian stimulation in IVF/ICSI: an individual participant data meta-analysis. Human Reproduction Update. 2025;31(2):116-132. doi:10.1093/humupd/dmae032
BibTeX
@article{Schouten2025,
author = {Schouten, Nienke and Wang, Rui and Torrance, Helen and Van Tilborg, Theodora and Bastu, Ercan and Bergh, Christina and D'Hooghe, Thomas and Friis Petersen, Jesper and Jayaprakasan, Kannamannadiar and Khalaf, Yacoub and Klinkert, Ellen and La Marca, Antonio and Vuong, Lan and Lapensée, Louise and Lensen, Sarah and Magnusson, Åsa and Allegra, Adolfo and Nyboe Andersen, Anders and Oudshoorn, Simone and Popovic-Todorovic, Biljana and Mol, Ben Willem and Eijkemans, Marinus and Broekmans, Frank},
title = {Development and validation of a gonadotropin dose selection model for optimized ovarian stimulation in IVF/ICSI: an individual participant data meta-analysis},
journal = {Human Reproduction Update},
year = {2025},
volume = {31},
number = {2},
pages = {116--132},
doi = {10.1093/humupd/dmae032}
}
EUVIMED